Coombes, R. C. http://orcid.org/0000-0002-4811-1100
Badman, P. D. http://orcid.org/0000-0002-0337-3190
Lozano-Kuehne, J. P. http://orcid.org/0000-0002-7372-0725
Liu, X.
Macpherson, I. R. http://orcid.org/0000-0003-4295-8885
Zubairi, I.
Baird, R. D. http://orcid.org/0000-0001-7071-6483
Rosenfeld, N. http://orcid.org/0000-0002-2825-4788
Garcia-Corbacho, J. http://orcid.org/0000-0002-6109-8449
Cresti, N. http://orcid.org/0000-0002-0495-4472
Plummer, R.
Armstrong, A.
Allerton, R.
Landers, D. http://orcid.org/0000-0001-8376-9779
Nicholas, H.
McLellan, L.
Lim, A.
Mouliere, F. http://orcid.org/0000-0001-7043-0514
Pardo, O. E. http://orcid.org/0000-0003-2223-1435
Ferguson, V.
Seckl, M. J. http://orcid.org/0000-0003-4078-2599
Article History
Received: 21 September 2021
Accepted: 12 May 2022
First Online: 10 June 2022
Change Date: 17 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-35969-4
Competing interests
: N.R. is co-founder and officer of Inivata, a company that commercialises technologies for ctDNA analysis. D.L. consults to Astrazeneca (AZ) and was an employee in the past. His research team has also received grant funding from AZ. He also has a Director role and is an employee of his own consultancy company DeLondra Oncology Ltd. RCC currently has a grant from AZ. I.M. consults to AZ. R.B. consults to AZ and has received grant funding, travel, accommodation, expenses from AZ. A.A. has received grant funding to her Institution from AZ. P.B., I.Z., X.L., J.P.L.K., H.N., M.S., N.C., E.P., L.M., A.L., F.M., O.P., R.A., J.G.C. and V.F. have indicated no competing interests.